July 8, 2007 — The U.S. Food and Drug Tenure (FDA) has advised healthcare professionals via news legal instrument of a possibility risk of sudden modality loss that may be attributed to use of phosphodiesterase 5 (PDE-5) inhibitors.
According to the news passing, sudden sense experience loss in one eye due to nonarteritic anterior ischemic optic neuropathy (NAION) has been reported in a size signal of patients taking sildenafil citrate (Viagra, made by Pfizer, Inc.), discount generic cialis soft tablets (Cialis, made by Lilly ICOS, LLC), and vardenafil HCl (Levitra, made by Bayer Pharmaceuticals Corp.) for the artistic style of erectile dysfunction (ED).
Buy Cheap Cialis Tadalafil Soft Tabs 20mg:
As of May 18, the FDA has received a amount of 43 postmarketing reports of ischemic optic neuropathy in patients using these drugs (sildenafil, n = 38; cialis, n = 4; vardenafil, n = 1). A legal age of these cases (36) appear to be of the NAION subtype; in 26 of these, the loss of experience has been described as continuing or permanent.
Because many of these adverse events were reported in patients with vascular risk factors for NAION that conjunction with those for ED (such as age older than 50 long time, low cup to disc quantitative relation, hypertension, diabetes, ventilation, etc), the causal role of PDE-5 inhibitors object unclear.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment